Nanoformulation Strategies for Cancer Treatment

<p>Section A: General consideration on cancer nanomedicines<br>1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges and future perspectives<br>2. Market research in cancer therapeutics: New and Generic Product Development<br>3. Regulatory perspectives of nanomedicines for cancer treatment</p> <p>Section B: Formulation technologies in cancer nanomedicines<br>4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy<br>5. Polymeric nanoparticles for potential drug delivery applications in cancer<br>6. Lipid-polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy<br>7. Metallic nanoparticles in drug delivery and cancer treatment<br>8. Liposomal nanotherapeutics in cancer treatment<br>9. Surface decoration strategies in nanomedicines for cancer treatment<br>10. Protein based nanomedicines as anticancer drug delivery platform<br>11. Phyto actives loaded nanocarriers for liver cancer treatment</p> <p>Section C: Innovative treatment strategies in cancer nanomedicines<br>12. Nanotechnology assisted medical devices in cancer treatment<br>13. Immunotherapy as a boon in cancer treatment<br>14. Antibody-drug combination therapy in cancer treatment<br>15. Immune-chemo combination therapy in cancer treatment</p> <p>Section D: Clinical perspectives in cancer nanomedicines<br>16. Formulation and biological stability of the nanomedicines in cancer treatment<br>17. Nanotoxicology profiling of cancer nanomedicines<br>18. Clinical translation status of nanoformulations</p> <p>Section E: Regulatory perspectives in cancer nanomedicines<br>19. GLP and cGMP requirements in the development of cancer nanomedicines<br>20. Quality by Design approach for systematic development of nanopharmaceutical products</p>